NO20034278L - Sammensetninger og fremgangsmåter til behandling av HCV- infeksjoner - Google Patents
Sammensetninger og fremgangsmåter til behandling av HCV- infeksjonerInfo
- Publication number
- NO20034278L NO20034278L NO20034278A NO20034278A NO20034278L NO 20034278 L NO20034278 L NO 20034278L NO 20034278 A NO20034278 A NO 20034278A NO 20034278 A NO20034278 A NO 20034278A NO 20034278 L NO20034278 L NO 20034278L
- Authority
- NO
- Norway
- Prior art keywords
- methods
- compositions
- hcv
- treating hcv
- hcv infections
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0018—Culture media for cell or tissue culture
- C12N5/0031—Serum-free culture media
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0018—Culture media for cell or tissue culture
- C12N5/0037—Serum-free medium, which may still contain naturally-sourced components
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/067—Hepatocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C12N2500/20—Transition metals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C12N2500/20—Transition metals
- C12N2500/24—Iron; Fe chelators; Transferrin
- C12N2500/25—Insulin-transferrin; Insulin-transferrin-selenium
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/36—Lipids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/46—Amines, e.g. putrescine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/11—Epidermal growth factor [EGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/12—Hepatocyte growth factor [HGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/18—Liver cell growth factor (LCGF, Gly-His-Lys)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/30—Hormones
- C12N2501/335—Glucagon; Glucagon-like peptide [GLP]; Exendin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/30—Hormones
- C12N2501/375—Thyroid stimulating hormone [TSH]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/30—Hormones
- C12N2501/38—Hormones with nuclear receptors
- C12N2501/39—Steroid hormones
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Semiconductor Lasers (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US27917401P | 2001-03-27 | 2001-03-27 | |
PCT/US2002/009685 WO2002077206A1 (en) | 2001-03-27 | 2002-03-27 | Compositiona and methods useful for hcv infection |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20034278D0 NO20034278D0 (no) | 2003-09-25 |
NO20034278L true NO20034278L (no) | 2003-11-25 |
Family
ID=23067944
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20034278A NO20034278L (no) | 2001-03-27 | 2003-09-25 | Sammensetninger og fremgangsmåter til behandling av HCV- infeksjoner |
Country Status (15)
Country | Link |
---|---|
US (3) | US7879606B2 (no) |
EP (1) | EP1381673B1 (no) |
JP (2) | JP4499990B2 (no) |
KR (1) | KR100947911B1 (no) |
CN (1) | CN100362095C (no) |
AT (1) | ATE431396T1 (no) |
CA (1) | CA2441688C (no) |
DE (1) | DE60232322D1 (no) |
ES (1) | ES2328466T3 (no) |
HK (1) | HK1063334A1 (no) |
MX (1) | MXPA03008882A (no) |
NO (1) | NO20034278L (no) |
NZ (1) | NZ528462A (no) |
WO (1) | WO2002077206A1 (no) |
ZA (1) | ZA200307373B (no) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA979327B (en) | 1996-10-18 | 1998-05-11 | Vertex Pharma | Inhibitors of serine proteases, particularly hepatitis C virus NS3 protease. |
SV2003000617A (es) | 2000-08-31 | 2003-01-13 | Lilly Co Eli | Inhibidores de la proteasa peptidomimetica ref. x-14912m |
JP2006508662A (ja) | 2002-12-04 | 2006-03-16 | アプレラ コーポレイション | ポリヌクレオチドの多重増幅 |
TWI359147B (en) | 2003-09-05 | 2012-03-01 | Vertex Pharma | Inhibitors of serine proteases, particularly hcv n |
EP1689857A1 (en) * | 2003-12-01 | 2006-08-16 | Vertex Pharmaceuticals Incorporated | Compositions comprising fetal liver cells and methods useful for hcv infection |
US8399615B2 (en) | 2005-08-19 | 2013-03-19 | Vertex Pharmaceuticals Incorporated | Processes and intermediates |
US7964624B1 (en) | 2005-08-26 | 2011-06-21 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases |
AR055395A1 (es) | 2005-08-26 | 2007-08-22 | Vertex Pharma | Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c |
CA2643688A1 (en) | 2006-02-27 | 2007-08-30 | Vertex Pharmaceuticals Incorporated | Co-crystals and pharmaceutical compositions comprising the same |
KR20080112303A (ko) | 2006-03-16 | 2008-12-24 | 버텍스 파마슈티칼스 인코포레이티드 | 중수소화 c형 간염 프로테아제 억제제 |
CA2679426A1 (en) | 2007-02-27 | 2008-09-04 | Luc Farmer | Inhibitors of serine proteases |
KR20090115970A (ko) | 2007-02-27 | 2009-11-10 | 버텍스 파마슈티칼스 인코포레이티드 | 공-결정 및 그를 포함하는 제약 조성물 |
JP5443360B2 (ja) | 2007-08-30 | 2014-03-19 | バーテックス ファーマシューティカルズ インコーポレイテッド | 共結晶体およびそれを含む医薬組成物 |
CA2707841C (en) * | 2007-12-04 | 2017-10-24 | Prionics Ag | Kit and method for detecting bovine viral diarrhea virus in tissue samples |
CN101906487A (zh) * | 2010-08-05 | 2010-12-08 | 中国兽医药品监察所 | 一种猪瘟病毒核酸标准物质的制备方法 |
CN104755606B (zh) * | 2012-08-31 | 2019-04-12 | 阿尔伯达大学董事会 | 用于产生具有原代人肝细胞表型的细胞的方法和组合物 |
EP3289074B1 (en) | 2015-04-28 | 2023-10-04 | Université de Strasbourg | Clinical gene signature-based human cell culture model and uses thereof |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5529920A (en) | 1988-12-14 | 1996-06-25 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Human liver epithelial cell line and culture media therefor |
US5849686A (en) | 1991-03-11 | 1998-12-15 | Creative Biomolecules, Inc. | Morphogen-induced liver regeneration |
US6069005A (en) | 1991-08-07 | 2000-05-30 | Albert Einstein College Of Medicine Of Yeshwa University | Hapatoblasts and method of isolating same |
JPH07501206A (ja) | 1991-08-07 | 1995-02-09 | イェシバ・ユニバーシティ | 前駆肝細胞の増殖 |
ES2260759T3 (es) | 1993-11-19 | 2006-11-01 | Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University | Hepatoblastos y metodo de aislamiento de los mismos. |
KR19990036028A (ko) * | 1995-08-01 | 1999-05-25 | 다니엘 케르니 | 일본뇌염 백신의 공업적인 생산방법 및 이에 의한 백신 |
US6127116A (en) | 1995-08-29 | 2000-10-03 | Washington University | Functional DNA clone for hepatitis C virus (HCV) and uses thereof |
ATE550429T1 (de) * | 1996-11-20 | 2012-04-15 | Crucell Holland Bv | Adenovirus-zusammensetzungen erhältlich durch ein verbessertes produktions- und reinigungsverfahren |
US6133030A (en) * | 1997-05-14 | 2000-10-17 | The General Hospital Corporation | Co-cultivation of cells in a micropatterned configuration |
FR2775983B1 (fr) * | 1998-03-13 | 2000-11-10 | Pasteur Merieux Serums Vacc | Milieu et procede de propagation et de multiplication virales |
EP0972828A1 (en) * | 1998-06-24 | 2000-01-19 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Process for the in vitro replication of HCV |
AU774566B2 (en) * | 1998-12-07 | 2004-07-01 | Duke University | A method of isolating stem cells |
KR100873690B1 (ko) | 1999-01-19 | 2008-12-12 | 유니버시티 오브 노스캐롤라이나 앳 채플 힐 | 인간 간 전구세포 |
US20020187133A1 (en) | 1999-10-01 | 2002-12-12 | Hiroshi Kubota | Methods of isolating bipotent hepatic progenitor cells |
CA2397927A1 (en) | 2000-01-19 | 2001-07-26 | University Of North Carolina At Chapel Hill | Liver tissue source |
ATE510905T1 (de) | 2000-10-03 | 2011-06-15 | Univ North Carolina | Verfahren zur isolierung von bipotenten lebervorläuferzellen |
KR100887623B1 (ko) | 2000-10-03 | 2009-03-11 | 유니버시티 오브 노스 캐롤라이나 | 간 전구세포의 클론 증식방법 |
US7183095B2 (en) | 2001-03-09 | 2007-02-27 | The Regents Of The University Of California | Cell culture system for synthesis of infectious hepatitis C virus |
WO2004003172A2 (en) * | 2002-07-01 | 2004-01-08 | Pharmacia Corporation | Esm-1 gene differentially expressed in angiogenesis, antagonists thereof, and methods of using the same |
-
2002
- 2002-03-27 EP EP20020753872 patent/EP1381673B1/en not_active Expired - Lifetime
- 2002-03-27 US US10/109,298 patent/US7879606B2/en not_active Expired - Fee Related
- 2002-03-27 DE DE60232322T patent/DE60232322D1/de not_active Expired - Lifetime
- 2002-03-27 CN CNB028074181A patent/CN100362095C/zh not_active Expired - Fee Related
- 2002-03-27 MX MXPA03008882A patent/MXPA03008882A/es active IP Right Grant
- 2002-03-27 AT AT02753872T patent/ATE431396T1/de not_active IP Right Cessation
- 2002-03-27 KR KR20037012663A patent/KR100947911B1/ko not_active IP Right Cessation
- 2002-03-27 NZ NZ528462A patent/NZ528462A/en not_active IP Right Cessation
- 2002-03-27 WO PCT/US2002/009685 patent/WO2002077206A1/en active Application Filing
- 2002-03-27 CA CA 2441688 patent/CA2441688C/en not_active Expired - Fee Related
- 2002-03-27 JP JP2002576649A patent/JP4499990B2/ja not_active Expired - Fee Related
- 2002-03-27 ES ES02753872T patent/ES2328466T3/es not_active Expired - Lifetime
-
2003
- 2003-09-22 ZA ZA2003/07373A patent/ZA200307373B/en unknown
- 2003-09-25 NO NO20034278A patent/NO20034278L/no not_active Application Discontinuation
-
2004
- 2004-07-20 HK HK04105318A patent/HK1063334A1/xx not_active IP Right Cessation
-
2010
- 2010-02-19 JP JP2010034585A patent/JP2010142249A/ja active Pending
-
2011
- 2011-01-25 US US13/013,758 patent/US8211696B2/en not_active Expired - Fee Related
-
2012
- 2012-06-29 US US13/538,777 patent/US20130071834A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
KR100947911B1 (ko) | 2010-03-17 |
JP4499990B2 (ja) | 2010-07-14 |
US20110229874A1 (en) | 2011-09-22 |
EP1381673A1 (en) | 2004-01-21 |
CA2441688C (en) | 2014-01-21 |
US8211696B2 (en) | 2012-07-03 |
US20130071834A1 (en) | 2013-03-21 |
ZA200307373B (en) | 2005-06-29 |
WO2002077206A1 (en) | 2002-10-03 |
ATE431396T1 (de) | 2009-05-15 |
DE60232322D1 (de) | 2009-06-25 |
CA2441688A1 (en) | 2002-10-03 |
EP1381673A4 (en) | 2004-11-10 |
CN1511190A (zh) | 2004-07-07 |
JP2004529637A (ja) | 2004-09-30 |
US20020142449A1 (en) | 2002-10-03 |
NZ528462A (en) | 2005-11-25 |
CN100362095C (zh) | 2008-01-16 |
MXPA03008882A (es) | 2003-12-08 |
KR20040012739A (ko) | 2004-02-11 |
ES2328466T3 (es) | 2009-11-13 |
JP2010142249A (ja) | 2010-07-01 |
HK1063334A1 (en) | 2004-12-24 |
US7879606B2 (en) | 2011-02-01 |
EP1381673B1 (en) | 2009-05-13 |
NO20034278D0 (no) | 2003-09-25 |
WO2002077206A9 (en) | 2004-02-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20034278D0 (no) | Sammensetninger og fremgangsmåter til behandling av HCV- infeksjoner | |
DE60230672D1 (de) | Nukleinsäureanreicherung | |
GEP20094785B (en) | Pyrrolopyrazoles, potent kinase inhibitors | |
DE60232234D1 (de) | Verfahren zur kultivierung von circovirus | |
MXPA06011046A (es) | Ciertos compuestos basados en triazol, composiciones, y usos de los mismos. | |
EA200601555A1 (ru) | Замещенные индазол-о-глюкозиды | |
EA200601554A1 (ru) | Замещенные индол-о-глюкозиды | |
DE602004006433D1 (de) | Pyrrol-substituierte indole als inhibitoren von pai-1 | |
TW200628159A (en) | IL-12 modulatory compounds | |
TW200720256A (en) | IL-12 modulatory compounds | |
DK0922102T3 (da) | Receptor-agonister af hepatocyt-vækstfaktor og anvendelser deraf | |
TW200621253A (en) | 2-amido-thiazole-based compounds exhibiting atp-utilizing enzyme inhibitory activity, and compositions, and uses thereof | |
UA86042C2 (en) | Substituted indazole-o-glucosides | |
TNSN05254A1 (en) | Derivatives of 2-acylamino-4-phenylthiazole, preparation method thereof and application of same in therapeutics | |
TW200732349A (en) | Anti-OX40L antibodies and methods using same | |
NO20055741D0 (no) | Nye kjemiske forbindelser | |
ATE453328T1 (de) | Verbesserte formulierung zur bereitstellung eines magensaftresitenten beschichtungsmaterials | |
DE50208918D1 (de) | 6-aminomorphinanderivate, herstellungsverfahren dafür und deren verwendung | |
DE69913712T2 (de) | Inhibitoren der bakteriellen nad synthetase | |
HRP20051005A2 (en) | Process for the preparation of nonpeptide substituted spirobenzoazepine derivatives | |
TW200716130A (en) | Purified form of tanaproget | |
ATE335739T1 (de) | Cak inhibitoren und deren verwendungen | |
TR200402030T4 (tr) | İkame edilen I-aminobutan-3-ol-türevleri | |
ATE532875T1 (de) | Reinigungsverfahren und ihre verwendungen | |
DE602004018811D1 (de) | Pyrrolidinylharnstoffderivate als angiogeneseinhibitoren |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |